
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics PLC is advancing its clinical-stage pipeline of next-generation programmed T-cell therapies, with Obe-cel positioned to expand its label and potentially outperform standard-of-care CAR-T therapies. The company anticipates achieving gross margins of 60-70% through enhanced manufacturing utilization and process improvements, which could positively impact overall financial performance. Additionally, the demonstrated safety and mortality benefits of its Aucazyl product in real-world applications further solidify Autolus’s competitive edge in the treatment landscape for cancer therapy.
Bears say
Autolus Therapeutics's stock is facing a negative outlook primarily due to anticipated flat sales in Q3 2025, influenced by changes in CMS reimbursement policies, raising concerns about the stability of revenue streams. Additionally, the early results from the SLDAI-2K study suggest limited effectiveness, with only two out of three patients showing significant clinical improvements, which may hinder the company's ability to meet its forecasts for CAR-T therapeutics production. The emergence of complications in patient outcomes, including relapse and minimal residual disease, further contributes to uncertainties regarding the efficacy and commercial viability of its therapies.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares